Vaxart Establishes New Board Committees for Clinical Oversight and Stockholder Engagement

Event Summary: On August 21, 2026, Vaxart, Inc.'s Board of Directors established two new committees: the Clinical and Regulatory Affairs Committee and the Stockholder Engagement Committee.

Committee Details:

• Clinical and Regulatory Affairs Committee: This committee will oversee the company's research, clinical, and regulatory programs. The appointed members are James B. Breitmeyer, M.D., Ph.D. (Chair) and David Wheadon, M.D.
• Stockholder Engagement Committee: This committee is tasked with overseeing and advancing the company's relationship with its stockholders. The initial members are W. Mark Watson (Interim Chair) and Steven Lo.

Analyst's Notes: The formation of these committees represents a development in Vaxart's corporate governance structure. The Clinical and Regulatory Affairs Committee formalizes oversight of the company's core scientific operations, a crucial function for a clinical-stage biotechnology company. The creation of the Stockholder Engagement Committee is particularly noteworthy. The filing mentions it is pursuant to a 'Cooperation Agreement' dated July 1, 2026, and that a new director is expected to be appointed in the future to serve as its Chair. This suggests the committee's formation may be a result of a settlement or agreement with an activist investor or a significant shareholder group, aimed at improving communication and alignment between the board and its stockholders.